Publication: Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
Issued Date
2019-05-04
Resource Type
ISSN
25787470
25787489
25787489
Other identifier(s)
2-s2.0-85076381646
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
HIV Research and Clinical Practice. Vol.20, No.3 (2019), 73-81
Suggested Citation
Yeon Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, Sang Youn Yang, Susan Guo, Ya Pei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Research and Clinical Practice. Vol.20, No.3 (2019), 73-81. doi:10.1080/15284336.2019.1589232 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51650
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
Other Contributor(s)
National Center for Global Health and Medicine
Chungnam National University
Khon Kaen University
The HIV Netherlands Australia Thailand Research Collaboration
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Brighton and Sussex University Hospitals NHS Trust
Gilead Sciences Incorporated
Chiang Mai University
Thai Red Cross AIDS Research Centre
Chungnam National University
Khon Kaen University
The HIV Netherlands Australia Thailand Research Collaboration
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Brighton and Sussex University Hospitals NHS Trust
Gilead Sciences Incorporated
Chiang Mai University
Thai Red Cross AIDS Research Centre
Abstract
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian participants infected with human immunodeficiency virus (HIV)-1 through 96 or 144 weeks. Objective: In Asian population requiring treatment, it is imperative to have data specific to this group, particularly as there is a general concern that Asians with lower body weight have increased risk of tenofovir disoproxil fumarate (TDF)-related renal dysfunction. Methods: Studies -104 and 111 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-naive participants, comparing E/C/F/TAF versus E/C/F/TDF. Study 109 was a randomized, open-label, 96-week study conducted in virologically suppressed, ART-experienced participants, who switched to E/C/F/TAF from ritonavir/cobicistat-boosted atazanavir ATV+(RTV or COBI) + F/TDF regimens, from non-nucleoside reverse transcriptase inhibitors (NNRTI) + F/TDF regimens, or from E/C/F/TDF. Study 112 was a single arm, open-label, 144-week study conducted in HIV suppressed, ART-experienced participants with mild-moderate renal impairment, who switched to E/C/F/TAF. Results: Asian participants in these studies had sustained efficacy safety and tolerability. In Study 104/111, Asian participants achieved 93% virologic suppression on TAF vs 88% on TDF at week 144. At baseline, there were numerically more Asians with median CD4 counts < 200 cells/uL and VL > 100,000 c/mL. In Study 109, 95% of Asians on TAF vs 86% on TDF maintained virologic suppression at week 96. Lastly, in Study 112, 91% maintained virologic suppression at week 144. There were no discontinuations due to renal AE, no cases of PRT or Fanconi syndrome in any of the studies.